Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C3AR1 | Q16581 | 1/20 | 0.39 |
| ▸ | FURIN | P09958 | 7/20 | 0.36 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.35 |
| ▸ | CTSB | P07858 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.34 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.34 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.33 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KLK7 | P49862 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.33 |
| ▸ | GNPAT | O15228 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31319761 | 0.87 | C3AR1 (0.41) | C3AR1FURINCTDSP1CTSBPRSS1 | |
| SCHEMBL29620243 | 0.87 | C3AR1 (0.42) | C3AR1FURINCTDSP1PRSS1NOD1 | |
| SCHEMBL24191073 | 0.86 | C3AR1 (0.42) | C3AR1FURINCTDSP1CTSBPOLB | |
| SCHEMBL30317564 | 0.86 | C3AR1 (0.42) | C3AR1FURINCTDSP1CTSBPOLB | |
| SCHEMBL23629902 | 0.82 | MEN1 (0.44) | C3AR1FURINPRSS1MEN1KMT2A | |
| SCHEMBL29385639 | 0.81 | C3AR1 (0.45) | C3AR1FURINCTDSP1POLBNOD1 | |
| SCHEMBL31666024 | 0.81 | NOD1 (0.40) | C3AR1FURINCTDSP1PRSS1NOD1 | |
| SCHEMBL18688864 | 0.81 | GNPAT (0.45) | C3AR1FURINCTDSP1NOD1FOLH1 | |
| SCHEMBL28574926 | 0.81 | GNPAT (0.45) | C3AR1FURINCTDSP1NOD1FOLH1 | |
| Trifluoroacetic Acid SCHEMBL23630136 | 0.80 | QRFPR (0.39) | C3AR1FURINCTDSP1CTSBPRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2544701-B1 | POLYMERIC DRUG DELIVERY CONJUGATES AND METHODS OF MAKING AND USING THEREOF | UNIV UTAH RES FOUND (US) | 2019-08-14 | — | — | EP | disclosed |
| US-9289510-B2 | Polymeric drug delivery conjugates and methods of making and using thereof | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2016-03-22 | — | — | US | disclosed |
| US-20130156722-A1 | POLYMERIC DRUG DELIVERY CONJUGATES AND METHODS OF MAKING AND USING THEREOF | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2013-06-20 | — | — | US | disclosed |
| EP-2544701-A2 | POLYMERIC DRUG DELIVERY CONJUGATES AND METHODS OF MAKING AND USING THEREOF | University of Utah Research Foundation (US) | 2013-01-16 | — | — | EP | disclosed |
| WO-2011112482-A2 | POLYMERIC DRUG DELIVERY CONJUGATES AND METHODS OF MAKING AND USING THEREOF | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2011-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130156722-A1 | POLYMERIC DRUG DELIVERY CONJUGATES AND METHODS OF MAKING AND USING THEREOF | CD44, MMP7, MMP26 | C3AR1 1563/4885FURIN 76/4885CTDSP1 605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.